Series: The T Files — Series 3: “The Injection Dark Ages"
Subtitle: 50 years of yo-yo shots, hormonal roller coasters, and the pharmacology nobody warned you about
Post: 4 of 5
Tags: testosterone undecanoate, Aveed, Nebido, POME, pulmonary oil microembolism, REMS, FDA, injectable testosterone, adverse effects
Word Count: ~1,100
By the mid-2000s, the testosterone therapy field was looking for a better long-acting injectable. The standard formulations — enanthate and cypionate — required shots every two to four weeks and produced the pharmacokinetic rollercoaster that everyone knew about and nobody had fully fixed. What the field wanted was an injectable that lasted longer, with more stable levels, at a lower dosing frequency.
Testosterone undecanoate — marketed in Europe as Nebido since 2004 and in the United States as Aveed since 2014 after a prolonged regulatory review — delivered on the frequency problem. It is dosed at 750mg intramuscularly, followed by a repeat dose four weeks later, then every ten weeks thereafter. Ten weeks between injections. Five injections per year instead of twelve to twenty-six.
It also carried a rare but genuinely alarming risk that required a full FDA Risk Evaluation and Mitigation Strategy program just to make it available. That risk is called POME — pulmonary oil microembolism — and it is exactly as unsettling as it sounds.
What Is POME?
POME stands for pulmonary oil microembolism. It occurs when tiny oil droplets from an oil-based injectable medication enter the systemic circulation — typically through inadvertent intravenous injection or venous penetration during IM administration — and reach the pulmonary vasculature.
Testosterone undecanoate (TU) is prepared in refined castor oil, 250mg/mL in 3mL vials. The castor oil vehicle is what enables TU’s extended release pharmacokinetics. It is also the source of the POME risk: if any of that oil reaches the bloodstream rather than remaining in the muscle tissue, it can travel to the lungs.
The symptoms of POME are rapid and alarming. According to the Aveed product labeling and FDA communications, they include:
- An urge to cough (often described as sudden, unexpected, and intense)
- Shortness of breath (dyspnea)
- Throat tightening
- Chest pain
- Dizziness
- In severe cases, syncope (loss of consciousness)
These symptoms typically occur within minutes of injection — some reports describe onset within seconds. POME is not a delayed adverse reaction. It is an acute, intra-procedure or immediately post-procedure event.
The Anaphylaxis Co-Risk
POME is not the only reason Aveed carries a Boxed Warning. TU injections also carry a risk of anaphylaxis — a systemic allergic reaction that, in severe cases, can be life-threatening.
Anaphylaxis and POME can present with overlapping symptoms (difficulty breathing, chest tightness, dizziness) which makes rapid clinical differentiation during an acute event challenging. Together, these two risks drove the FDA’s decision that testosterone undecanoate could not simply be dispensed from a pharmacy and injected at home or in a primary care office without specific safeguards.
What a REMS Program Is and Why This One Exists
REMS stands for Risk Evaluation and Mitigation Strategy. The FDA requires REMS programs for drugs whose benefits are judged sufficient to keep them on the market, but whose risks are serious enough that standard prescribing and dispensing practices are inadequate to protect patients.
The Aveed REMS program has a specific and non-negotiable requirement: every injection of testosterone undecanoate must be administered by a healthcare provider in a healthcare setting equipped to manage serious adverse reactions. After each injection, the patient must be observed for at least 30 minutes before leaving.
This is not a recommendation. It is a program condition for the drug’s continued availability in the United States.
The 30-minute observation window exists because POME and anaphylaxis onset is acute. If something goes wrong, it will go wrong quickly, and it will require immediate intervention — airway management, epinephrine, potentially emergency services. A patient who receives a TU injection at home, experiences POME onset ten minutes later, and is alone is in a very dangerous situation.
The Regulatory History That Led Here
The road to Aveed’s US approval was not smooth. Testosterone undecanoate had been available in Europe as Nebido since 2004 and was already widely used in dozens of countries. The FDA initially reviewed TU for US approval in 2009 — and rejected it, citing concerns about the POME risk.
A second FDA review in 2012 also resulted in rejection. The FDA’s concern was not that POME was frequent — it is rare — but that it was unpredictable and severe when it did occur, and that the available risk management framework at the time was inadequate.
Endo Pharmaceuticals eventually developed the REMS program structure that satisfied the FDA, and Aveed was approved in March 2014 with that program in place. The entire approval process, from initial application to US market availability, took approximately five years — largely due to the POME risk management question.
This regulatory history is instructive. The FDA’s position was essentially: a therapy that requires a minimum 30-minute supervised observation after every dose is not suitable for unsupervised administration, regardless of how convenient the every-ten-weeks dosing schedule appears.
The Pharmacokinetics of TU: Actually Quite Good
Here is the irony: setting aside the POME risk, testosterone undecanoate’s pharmacokinetics are meaningfully better than enanthate or cypionate. The mean peak serum testosterone of approximately 813 ng/dL is within the physiological range — not supratherapeutic in the same extreme sense as TE or TC peaks. The trough at week ten averages 323–339 ng/dL, just above the hypogonadal threshold.
The PK profile doesn’t demonstrate the extreme supraphysiological spikes that characterize the older formulations. The peaks and troughs are gentler. And five injections per year instead of twelve to twenty-six is, objectively, a significant reduction in treatment burden.
The adverse effects beyond POME and anaphylaxis are relatively unremarkable: acne (incidence above 3% in clinical trials), injection site pain, and increased PSA — all common to injectable TRT generally.
TU is, in the narrow pharmacokinetic sense, a more physiological injectable testosterone than its predecessors. The problem is that “more physiological” got bundled with “requires clinical supervision for every dose indefinitely.”
The Practical Implications
For most patients, the REMS requirement effectively rules out testosterone undecanoate as a practical long-term TRT option. Five clinic visits per year for 30-minute post-injection observation is a meaningful time and logistics burden. Many primary care physicians and even some endocrinologists do not administer Aveed because their practice settings aren’t configured for post-injection monitoring.
The drug remains available and is used in practice, but it occupies a narrow clinical niche — patients who specifically benefit from the low injection frequency, whose clinical providers have the infrastructure to administer it properly, and for whom the REMS requirements are workable.
That’s a fairly small population within the already-niche world of injection-based TRT.
The larger lesson: each attempt to improve injectable testosterone — from propionate’s every-three-days schedule to enanthate’s rollercoaster to undecanoate’s POME risk — introduced its own new set of problems. The injection route, despite decades of pharmaceutical development, never quite solved all of its issues simultaneously. Which brings us to the final post in this series: why men ultimately started quitting injectable TRT in large numbers — and what that rejection pushed the field to develop next.
Next time: Adherence data on injectable TRT is uncomfortable reading. We look at the documented reasons men quit injections in year one — injection site pain, mood volatility, frequency burden — and how patient dissatisfaction became the forcing function that accelerated the development of transdermal delivery systems. The 1990 consensus finally found its answer, but it took another decade to arrive.
